Results 71 to 80 of about 89,572 (287)

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

Annals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki, Tetsuya Abe, Hironori Fujieda, Shigenori Kadowaki, Tsutomu Tanaka, Masahiro Tajika, Koji Komori, Seiji Ito, Isao Oze, Kei Muro   +9 more
wiley   +1 more source

Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2

The World Journal of Men's Health, 2023
Purpose: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic agent because of its tumor selectivity and its ability to induce apoptosis in cancer cells while sparing most normal cells.
Won Hyeok Lee, Seong Cheol Kim, Song Hee Kim, Ji Hyung Yoon, Kyung Hyun Moon, Sang Hyeon Cheon, Taekmin Kwon, Young Min Kim, Jeong Woo Park, Sang Hun Lee, Jeong Min Lee, Sungchan Park, Benjamin I Chung   +12 more
doaj   +1 more source

Systematic Review and Meta‐Analysis on the Efficacy and Safety of Salvage Esophagectomy for T4 Esophageal Squamous Cell Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
This meta‐analysis of 208 cases shows that salvage esophagectomy for cT4 esophageal squamous cell carcinoma achieves a 72% R0 resection rate, offering a curative pathway for selected patients. However, it remains a high‐risk procedure with an 18% anastomotic leak rate and 30% major complications (Clavien–Dindo ≥ III).
Makoto Sakai, Kengo Kuriyama, Kazue Nagai, Ken Shirabe, Hiroshi Saeki   +4 more
wiley   +1 more source

Survival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care setting [PDF]

Introduction: The aim of this study was to evaluate overall survival of men who received systemic therapy with docetaxel for metastatic castration- resistant prostate cancer (MCRPC) in rural Nordland County, Norway.
Nieder, Carsten, Carsten Nieder, Haukland, Ellinor Christin, Ellinor Haukland, Stanisavljevic, Luka, Astrid Dalhaug, Luka Stanisavljevic, Dalhaug, Astrid   +7 more
core   +1 more source

AI‐Driven Cancer Multi‐Omics: A Review From the Data Pipeline Perspective

Advanced Intelligent Discovery, EarlyView.
The exponential growth of cancer multi‐omics data brings opportunities and challenges for precision oncology. This review systematically examines AI's role in addressing these challenges, covering generative models, integration architectures, Explainable AI for clinical trust, clinical applications, and key directions for clinical translation.
Shilong Liu, Shunxiang Li, Kun Qian
wiley   +1 more source

In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Life Science Alliance, 2020
A whole genome in vivo CRISPR/Cas9 screen identifies TCEAL1 as a potential target to sensitise prostate cancer cells to docetaxel to improve the efficacy of chemotherapy.
Linda K Rushworth, Victoria Harle, Peter Repiscak, William Clark, Robin Shaw, Holly Hall, Martin Bushell, Hing Y Leung, Rachana Patel   +8 more
doaj   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK

Journal of Experimental & Clinical Cancer Research, 2011
Objective To investigate the effects of ulinastatin and docetaxel on invasion of breast cancer cells and expression of uPA, uPAR and ERK, breast cancer MDA-MB-231 and MCF-7 cells.
Wang Hong, Zhong Biao, Zhao Xiaoliang, Gao Feng, Sun Xin, Luo Jie, Sun Zhijun   +6 more
doaj   +1 more source

Docetaxel cytotoxicity.

, 2016
Cytotoxic effects of docetaxel (DTX), docetaxel + ESWs (DTX ESWs), docetaxel-NBs (DTX NB), and docetaxel-loaded NBs + ESWs (DTX NB ESWs), in PC3 (panel A) and DU145 (panel B) cells.
Paolo Gontero (3534284), Antonino Battaglia (3534293), Roberta Cavalli (559998), Roberto Frairia (3597725), Rossella Peluso (3597722), Letizia Rinella (3597713), Nicoletta Fortunati (3597719), Monica Argenziano (703352), Patrizia D’Amelio (376080), Francesca Sassi (367185), Maria Graziella Catalano (3597716), Ornella Bosco (2559373), Francesca Marano (3597710)   +12 more
core   +1 more source

Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors

, 2020
Purpose: CPC634 is a novel nanoparticle entrapping docetaxel, developed to enhance the intratumoral chemotherapy exposure. This randomized cross-over study compared the intratumoral and plasma pharmacokinetics of CPC634 with conventional docetaxel ...
Moelker, Adriaan, Mathijssen, Ron H.J., van Hylckama Vlieg, Marte A.M., Rijcken, Cristianne J., Hanssen, Rob, van Eerden, Ruben A.G., Sparreboom, Alex, Hoop, Esther Oomende; id_orcid, Koolen, Stijn L.W., Atrafi, Florence, de Bruijn, Peter, Mathijssen, Ron H.J.; id_orcid, Lolkema, Martijn P., Eskens, Ferry A.L.M., Hoop, Esther Oomende   +14 more
core   +1 more source